SphingoTec Appoints Dr. Angelo Moesslang as Managing Director

Potsdam - June 2021. With the aim of steering SphingoTec towards the phase of commercial growth the management of SphingoTec has appointed Dr. Angelo Moesslang as an additional managing director and CFO, to support the improvement of patient management in critical care with innovative diagnostic solutions together with the entire team.

SphingoTec develops and markets innovative in vitro diagnostic solutions for novel biomarkers that support personalized medicine in critical care conditions. The biomarkers provide important, organ-specific information for monitoring acute courses of disease such as sepsis or acute renal failure. In this way, they support clinical decisions with the aim of improving patient management.

Brandenburg Kapital GmbH has been supporting the company since 2018.